Table 2.

Inclusion criteria

We include patients with all of the following criteria:
1)	Patients who have been made aware of the research purpose, interests, and disadvantages of the clinical trial before starting the examination - They understand this, and written informed consent is obtained. No substitution is allowed.
2)	Patients who are diagnosed with diffuse-type tenosynovial giant cell tumor (pigmented chorionic synovitis) or unresectable localized tenosynovial giant cell tumor occurring in the knee joint or ankle by radiological and pathological findings
3)	Patient with measurable lesion based on RECISTa v1.1 with at least one knee or ankle joint
4)	Patients who keep joint space in the knee or ankle joint in standing X-ray imaging
5)	Patients aged 20 years or older but less than 70 years old at the time of acquisition
6)	In the case of a pregnant woman, a patient whose pregnancy test, to be conducted during the screening period, is negative

^aRECIST response evaluation criteria in solid tumors